Imagenebio, Inc. quarterly report, Q2 FY2021

Business context and reporting period

Issuer identity: The supplied filing is Ikena Oncology, Inc.’s Form 10-Q for the quarter ended June 30, 2021, not Imagenebio, Inc. Verify the company and filing before relying on this summary. Ikena is an early-stage oncology drug developer with no approved products and no product-sale revenue. Its reported revenue is from a research and development collaboration with Bristol Myers Squibb (BMS).

Financial results and liquidity

• Six-month operating cash use was $28.9m, versus $17.6m in 2020; investing cash use was $1.0m. Financing provided $131.4m, primarily from the IPO.
• At June 30, cash and cash equivalents were $264.0m; current assets were $268.7m and current liabilities $30.5m. The company reported an accumulated deficit of $133.7m.
• The company reported no borrowings. Lease liabilities were $7.6m, with $9.1m of undiscounted minimum operating lease payments remaining.
• Management said cash on hand was expected to fund operating expenses and capital expenditures through 2023; this estimate depends on assumptions and may change.
• The March 2021 IPO raised approximately $131.3m net. Redeemable preferred stock converted into common stock at IPO closing.

Material changes versus prior comparable periods

• Q2 revenue increased 15%, while operating expenses doubled and net loss widened by $7.6m year over year. For the first half, revenue rose 11%, operating expenses rose 59%, and net loss widened by $10.4m.
• R&D growth reflected ongoing IK-930 and IK-412 IND-enabling and manufacturing work, discovery-stage research, and increased headcount. Lower activity in IK-175 and IK-007 partly offset the increases.
• G&A growth reflected increased staffing and higher audit, legal, consulting, and other public-company costs.
• Cash increased substantially following the IPO; the preferred-stock balance was eliminated on conversion to common equity.

Outlook, risks, contingencies and unusual items

• Management planned to submit an IND for IK-930 in Q4 2021 and expected to nominate an ERK5 development candidate and begin IND-enabling work in Q4 2021, targeting an IND in the second half of 2022. These are forward-looking plans, not assured outcomes.
• The IK-412 IND submission was delayed because a key manufacturing component was in high demand for COVID-19 vaccines and therapies. The company said it would update timing when supply could be reliably projected.
• IK-175 and IK-007 were in Phase 1 and Phase 1b development, respectively; the targeted oncology programs remained preclinical. The company disclosed that it had never successfully completed an oncology clinical trial.
• BMS had options to license IK-175 and IK-412, subject to the collaboration terms. Potential option fees, milestones and royalties are contingent; they are not assured revenue. Deferred collaboration revenue was $48.8m at June 30, expected to be recognized as services are performed through the research term.
• The company expects significant ongoing losses and increased R&D spending, and has no committed external funding source. Additional financing could dilute shareholders, restrict operations, or require licensing or other concessions.
• Key risks include clinical, regulatory and biomarker-defined market uncertainty; reliance on third-party manufacturers and CROs; single-source supply exposure; COVID-related operational disruptions; competition; and intellectual-property risks. No material litigation was reported. Management stated disclosure controls were effective at the reasonable-assurance level.

Most important facts for investors to verify

1. Confirm the issuer: the filing names Ikena Oncology, Inc., whereas the request metadata names Imagenebio, Inc.
2. Check subsequent filings for actual cash burn, any revisions to the stated runway through 2023, and additional financing.
3. Verify updated timelines and progress for IK-930, the ERK5 program, IK-412 supply and IND plans, and the partnered clinical programs.
4. Review BMS option status, collaboration revenue recognition, and whether any option fees, milestones or royalties were triggered.
5. Assess whether rising operating expenses and clinical/manufacturing risks remain consistent with the company’s development plans and available liquidity.